<DOC>
	<DOCNO>NCT01797926</DOCNO>
	<brief_summary>This three-period , three sequence , reference replicate , cross-over study determine bioequivalence two amlodipine losartan FDC tablet formulation FDC5/50 FDC5/100 ( GSK2944406 ; 5 mg amlodipine 50 mg 100 mg losartan ) reference amlodipine losartan tablet co-administered two group enrol 102 healthy adult male female subject fast condition . A description treatment provide : A ( Reference ) = 1 x 5 mg amlodipine tablet 1 x 50 mg losartan tablet . B ( FDC5/50 ) = 1 x 5 mg amlodipine 50 mg losartan tablet C ( Reference ) = 1 x 5 mg amlodipine tablet 1 x 100 mg losartan tablet D ( FDC5/100 ) = 1 x 5 mg amlodipine and100 mg losartan tablet The treatment administer accordance randomisation schedule . Group 1 : A → A → B A → B → A B → A → A Group 2 : C → C → D C → D → C D → C → C All subject attend screen visit within 28 day first dose period ( Day 1 ) . The baseline assessment conduct day first dose . In treatment period , subject admit clinic evening Day 1 . All subject receive single oral dose amlodipine losartan morning Day 1 . All subject remain clinical unit completion assessments 24 hour post-dose Day 2 include collection 24 hour post-dose PK sample . Subjects return clinic pharmacokinetic sample 36 , 48 , 72 96 hour post-dose . The three treatment period separate washout period 10-17 day . Upon completion last dosing period , early withdrawal , subject return clinical unit within 14-21 day follow visit .</brief_summary>
	<brief_title>Study Determine Bioequivalence Two Fixed Dose Combination ( FDC ) Tablet Formulations Amlodipine Losartan FDC5/50 FDC5/100 Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Age &amp; Gender : Male female 18 65 year age inclusive , time signing informed consent . Body weight &gt; = 50 kg body mass index ( BMI ) within range 18.5 24.9 kilogram/meter square . Alanine aminotransferase ( ALT ) alkaline phosphatase bilirubin &lt; or=1.5x upper limit normal ( ULN ) . Normal electrocardiogram ( ECG ) measurement . Average QT duration correct heart rate Fridericia 's formula ( QTcF ) &lt; 450 millisecond ( msec ) QTcF &lt; 480 msec subject Bundle Branch Block base average three ECGs obtain brief recording period . Female subject nonchild bear potential . Females child bear potential eligible enter pregnant willing use protocolspecified method contraception prevent pregnancy . Healthy determine responsible experienced physician , base medical Evaluation . Capable give write informed consent . The subject positive : drug/alcohol screen , Hepatitis , human immunodeficiency virus ( HIV ) screen Subject systolic blood pressure le 90 mmHg diastolic le 60 mm Hg irrespective associate symptoms time admission If drop 20 mmHg systolic pressure ( 10 mmHg drop diastolic ) 20 beat per minute increase heart rate supine measurement two minute stand time admission . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol time admission . Abuse alcohol Participated clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GlaxoSmithKline ( GSK ) Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Donation 500 milliliter ( mL ) blood within 56 day period . Pregnant lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Subject positive urinary cotinine level indicative use tobacco nicotinecontaining product within 6 month prior screen . Subjects asthma history asthma include childhood asthma . Unable refrain consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>Hypertension</keyword>
	<keyword>losartan</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>amlodipine</keyword>
</DOC>